Intra-Cellular's Lumateperone Poised For New Bipolar Depression Opportunity
Executive Summary
The company is on track to file an sNDA for lumateperone after a Phase III clinical trial met the primary endpoint in bipolar I and II disorder.
You may also be interested in...
Intra-Cellular's Lumateperone Brings Mixed Results In Bipolar Depression
Firm will discuss Phase III data with the US FDA, calling results from a successful Phase III monotherapy study robust despite second Phase III study's failure. Lumateperone is under review for schizophrenia, with a 27 September action date.
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US COVID-19 Vaccination Rollout On Track After Early Bumps, J.P. Morgan Panelists Say
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports